biostudies-literatureCarlson ALNIDDK NIH HHS178-189https://www.ebi.ac.uk/biostudies/studies/S-EPMC8971997biostudies-literatureUnknown24(3)<b><i>Introduction:</i></b> This trial assessed safety and effectiveness of an advanced hybrid closed-loop (AHCL) system with automated basal (Auto Basal) and automated bolus correction (Auto Correction) in adolescents and adults with type 1 diabetes (T1D). <b><i>Materials and Methods:</i></b> This multicenter single-arm study involved an intent-to-treat population of 157 individuals (39 adolescents aged 14-21 years and 118 adults aged ≥22-75 years) with T1D. Study participants used the MiniMed™ AHCL system during a baseline run-in period in which sensor-augmented pump +/- predictive low glucose management or Auto Basal was enabled for ∼14 days. Thereafter, Auto Basal and Auto Correction were enabled for a study phase (∼90 days), with glucose target set to 100 or 120 mg/dL for ∼45 days, foDiabetes technology & therapeuticsSafety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.PMC8971997P30 DK045735P30 DK020572P30 DK111022Kipnes MSShin JVella MSlover RHSherr JLChristiansen MGrosman BLilenquist DRThrasher JRCordero TLJonkers RAMRhinehart ASChen XKaiserman KBVigersky RAShulman DICarlson ALPop-Busui RRoy ABode BWLee SWReed JHCBrazg RLPhilis-Tsimikas AGarg SKfalseSafety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes.<b><i>Introduction:</i></b> This trial assessed safety and effectiveness of an advanced hybrid closed-loop (AHCL) system with automated basal (Auto Basal) and automated bolus correction (Auto Correction) in adolescents and adults with type 1 diabetes (T1D). <b><i>Materials and Methods:</i></b> This multicenter single-arm study involved an intent-to-treat population of 157 individuals (39 adolescents aged 14-21 years and 118 adults aged ≥22-75 years) with T1D. Study participants used the MiniMed™ AHCL system during a baseline run-in period in which sensor-augmented pump +/- predictive low glucose management or Auto Basal was enabled for ∼14 days. Thereafter, Auto Basal and Auto Correction were enabled for a study phase (∼90 days), with glucose target set to 100 or 120 mg/dL for ∼45 days, fo2022-01-01T00:00:00Z2022 Mar2025-04-04T12:45:21.389Z2025-04-04T12:45:21.389ZS-EPMC89719973469490910.1089/dia.2021.0319